Study Finds Potential New Drug Therapy for Crohn’s Disease

Ustekinumab Induces, Sustains Clinical Response in Patients

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn’s Disease, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the October 18, 2012 issue of the New England Journal of MedicineRead the full story from the UCSD Newsroom


Dr. William J. SandbornThe principal investigator of the study is Dr. William J. Sandborn, professor of medicine and chief of the Division of Gastroenterology at UCSD.  |  Read his academic profile  |  Read his clinical profile

Read the report of the study in the New England Journal of Medicine (full text UCSD only)

Citation of study report:  Sandborn WJ, Gasink C, Gao L-L, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P,  Ghosh S, de Villiers WJS, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG for the CERTIFI Study Group. N Engl J Med 2012; 367:1519-1528 October 18, 2012 DOI: 10.1056/NEJMoa1203572